Cetuximab biosimilar - Allergan/Amgen

Drug Profile

Cetuximab biosimilar - Allergan/Amgen

Alternative Names: ABP 494

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Actavis; Amgen
  • Developer Allergan; Amgen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Head and neck cancer

Most Recent Events

  • 09 Nov 2016 Preclinical trials in Colorectal cancer and Head and neck cancer in USA (unspecified route) (Amgen pipeline, November 2016)
  • 21 Apr 2015 Early research is underway in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top